Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The long search for a serotype independent pneumococcal vaccine

Full text
Author(s):
Converso, T. R. [1] ; Assoni, L. [1] ; Andre, G. O. [1] ; Darrieux, M. [1] ; Leite, L. C. C. [2]
Total Authors: 5
Affiliation:
[1] Univ Sao Francisco, Lab Biol Mol Microrganismos, Braganca Paulista, SP - Brazil
[2] Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: EXPERT REVIEW OF VACCINES; v. 19, n. 1 JAN 2020.
Web of Science Citations: 0
Abstract

Introduction: Serotype replacement - a consequence of polysaccharide vaccine use - will continue to drive the inclusion of new serotypes on conjugate vaccines, increasing production complexity and costs, and making an already expensive vaccine less accessible to developing countries, where prevalence is higher and resources available for health systems, scarcer. Serotype-independent formulations are a promising option, but so far they have not been successful in reducing colonization/transmission. Areas covered: Protein-based and whole-cell vaccine candidates studied in the past 30 years. Challenges for serotype-independent vaccine development and alternative approaches. Expert opinion: Clinical trials performed so far demonstrated the importance to establish more reliable animal models and better correlates of protection. Defining appropriate endpoints for clinical trials of serotype-independent vaccine candidates has been a challenge. Inhibition of colonization has been evaluated, but concern on the extent of bacterial elimination is still a matter of debate. Challenges on establishing representative sites for clinical trials, sample sizes and appropriate age groups are discussed. On a whole, although many challenges will have to be overcome, establishing protein-based antigens as serotype-independent vaccines is still the best alternative against the huge burden of pneumococcal diseases in the world. (AU)

FAPESP's process: 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma
Grantee:Luciana Cezar de Cerqueira Leite
Support Opportunities: Research Projects - Thematic Grants